Peptide having cancer selective translocation function and use thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 26, 2017
Issued Date -
N/A
app pub date -
Aug 11, 2016
filing date -
Sep 18, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A method of treating breast cancer is described, in which a peptide having cancer selective translocation function-doxoribicin conjugate is administered. The conjugate includes doxorubicin chemically linked to the N-terminus or C-terminus of a VEGF-binding protein transduction domain (VPTD) peptide represented as SEQ ID NO: 1, wherein the VPTD peptide and doxorubicin are linked to each other by a disulfide bond, and wherein the VPTD peptide binds specifically to vascular endothelial growth factor (VEGF) in tumor cells or tumor tissues.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully